A detailed history of Jpmorgan Chase & CO transactions in Precigen, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,078,789 shares of PGEN stock, worth $873,819. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,078,789
Previous 1,294,704 16.68%
Holding current value
$873,819
Previous $1.88 Million 9.22%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$1.27 - $1.75 $274,212 - $377,851
-215,915 Reduced 16.68%
1,078,789 $1.7 Million
Q1 2024

May 10, 2024

SELL
$1.21 - $1.75 $58,772 - $85,001
-48,572 Reduced 3.62%
1,294,704 $1.88 Million
Q4 2023

Feb 12, 2024

SELL
$0.89 - $1.41 $530 - $840
-596 Reduced 0.04%
1,343,276 $1.8 Million
Q3 2023

Nov 14, 2023

BUY
$1.08 - $1.85 $152,416 - $261,083
141,126 Added 11.73%
1,343,872 $1.91 Million
Q2 2023

Aug 11, 2023

SELL
$0.96 - $1.4 $9,358 - $13,647
-9,748 Reduced 0.8%
1,202,746 $1.38 Million
Q1 2023

May 18, 2023

BUY
$0.88 - $2.19 $82,234 - $204,651
93,448 Added 8.35%
1,212,494 $1.29 Million
Q1 2023

May 11, 2023

SELL
$0.88 - $2.19 $50,235 - $125,018
-57,086 Reduced 4.85%
1,119,046 $1.19 Million
Q4 2022

Feb 13, 2023

SELL
$1.27 - $2.26 $7,228 - $12,863
-5,692 Reduced 0.48%
1,176,132 $1.79 Million
Q3 2022

Nov 14, 2022

SELL
$1.41 - $2.79 $755,191 - $1.49 Million
-535,597 Reduced 31.19%
1,181,824 $2.51 Million
Q2 2022

Aug 11, 2022

SELL
$1.15 - $2.53 $42,420 - $93,324
-36,887 Reduced 2.1%
1,717,421 $2.3 Million
Q1 2022

May 11, 2022

SELL
$1.91 - $3.98 $292,971 - $610,484
-153,388 Reduced 8.04%
1,754,308 $3.7 Million
Q4 2021

Feb 10, 2022

BUY
$3.53 - $5.5 $229,831 - $358,094
65,108 Added 3.53%
1,907,696 $7.08 Million
Q3 2021

Nov 12, 2021

BUY
$4.99 - $6.55 $9.19 Million - $12.1 Million
1,842,588 New
1,842,588 $9.19 Million

Others Institutions Holding PGEN

About PRECIGEN, INC.


  • Ticker PGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 208,150,000
  • Market Cap $169M
  • Description
  • Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...
More about PGEN
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.